@cancertherapyadv.bsky.socialOur advisory board member @lungoncdoc.bsky.socialc recently spoke with us on his top picks of "practice-changing data" from the #WCLC26
Dr Singhi discusses several studies including ADAURA, HARMONi-2, and MAVERICK!
Read all his top picks here🔽
https://bit.ly/4j9o0QD
@onclive.bsky.social🫁 Lung cancer experts discuss strategies after immunotherapy in advanced squamous NSCLC. @narjustflorezmd.bsky.social @christianrolfo.bsky.social @cityofhope.bsky.social @osucccjames.bsky.social @danafarber.bsky.social @iaslc.bsky.social #WCLC26 #lcsm #oncology
@healthcare-europe.bsky.socialAfter treatment for #SCLC #lungcancer, patients often undergo prophylactic #radiotherapy to prevent #metastases in the brain. Now, a new study presented by Chad Rusthoven, MD, from 🇺🇸 @cumedicalschool.bsky.social at @iaslc.bsky.social's #WCLC26, shows that #MRI surveillance alone is enough.
@medthority.bsky.socialMissed out on #WCLC26? Visit Medthority for congress highlights that fit around your busy schedule, including key data from trials including MAVERICK, TAISHAN-302 and ARTEMIS-008
@alkpostitiveaust.bsky.socialYvonne Diaz & Ken Culver of ALK Positive Inc (US) with John & Jon, coming together at #WCLC26 in Seoul. ALK Positive Australia was just an idea 4 years ago, and now here we are at the global table working for better outcomes for all ALKies.
@cancertherapyadv.bsky.socialMore from #WCLC26!🫁
The phase 2 ARROS-1 trial assessed the efficacy and safety of zidesamtinib in patients with advanced/metastatic ROS1+ NSCLC who had not received a TKI.
The ORR was 93%, with a 12-month duration of response rate of 86%.
Full article: https://bit.ly/473asPb
@ipharmaservices.bsky.socialDESTINY-Lung04：#Enhertu 在1L HER2突变 #非小细胞肺癌 击败化疗+帕博利珠单抗。
• PFS: 14.3 vs 8.3月
• ORR: 70% vs 44.5%
• OS: 29.3 vs 33.1月
@ipharmaservices.bsky.socialDESTINY-Lung04: #Enhertu supera quimio+pembro em 1L #CPNPC HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notícias #mídia #CâncerDePulmão
@ipharmaservices.bsky.socialDESTINY-Lung04: #Enhertu batte chemio+pembro in 1L #NSCLC HER2+ • PFS: 14,3 vs 8,3m • ORR: 70% vs 44,5% • OS: 29,3 vs 33,1m
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notizie #media #TumoreAlPolmone
@cancertherapyadv.bsky.socialPumitamig and elfetabart drozuntecan (elfe-d) showed encouraging early efficacy + managable safety profile for patients with #SCLC
The ORR was 70.4% in patients with SCLC irrespective of smoking status or brain metastases.
From #WCLC26
Read more here: https://bit.ly/4iA2vIs
@cancertherapyadv.bsky.socialIpilimumab/nivolumab plus local consolidation therapy shortens survival in stage IV #NSCLC
Median OS for nivolumab/ipilimumab plus local consolidative therapy was 43.2 months versus 52.8 months without local consolidation therapy #WCLC26
Read: https://bit.ly/4y0cVWt
@cancertherapyadv.bsky.socialUpdated findings from TRUST-I & TRUST-II were presented in a poster at #WCLC26 🫁
Taletrectinib has shown durable ORRs & a manageable safety profile in patients with ROS1-positive #NSCLC, regardless of ROS1 fusion partners or prior chemo exposure.
Read: https://bit.ly/4y0b18h
@ipharmaservices.bsky.socialDESTINY-Lung04: #Enhertu schlägt Chemo+Pembro in 1L HER2+ #NSCLC
• PFS: 14,3 vs 8,3M
• ORR: 70% vs 44,5%
• OS: 29,3 vs 33,1M
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #Nachrichten #Medien #Lungenkrebs
@ipharmaservices.bsky.socialDESTINY-Lung04 : #Enhertu bat chimio+pembro en 1L #CBNPC HER2+
• SSP : 14,3 vs 8,3m
• TRG : 70% vs 44,5%
• SG : 29,3 vs 33,1m
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CancerDuPoumon #HER2
@ipharmaservices.bsky.socialDESTINY-Lung04: #Enhertu supera quimio+pembro en 1L #CPNM HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m
www.ipharmacenter.com/post/iaslc-2...
#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CáncerDePulmón #HER2
@brian-casey.bsky.socialMuch work remains to make LDCT lung cancer screening available to as many eligible people as possible while optimizing scanning protocols. That’s according to sessions at @iaslc.bsky.social's #WCLC26. Read more at bit.ly/4hdMrd5. #radiology
@alkpositiveuk.bsky.socialCould alectinib be used before surgery for ALK+ #lungcancer?
In the phase 2 NAUTIKA1 study, 55.8% had a major pathological response after 8 weeks of alectinib before surgery.
It’s early research, but an interesting new direction for ALK+ treatment.
@medpagetoday.comProgression-free survival improved in advanced HER2-mutant NSCLC when treatment started with trastuzumab deruxtecan instead of pembrolizumab (Keytruda) and chemotherapy, a large randomized trial showed. #WCLC26 @iaslc.bsky.social
https://www.medpagetoday.com/meetingcoverage/iaslc/123021
@lcrf.orgThe World Conference on Lung Cancer is the world’s largest multidisciplinary meeting dedicated to thoracic malignancies – and we'll be talking about the news from the event at our October 7 Together Separately livestream. Learn more and RSVP at lcrf.org/together. #LungCancer #WCLC26
@medpagetoday.comSecond-line treatment with an investigational anti-CTLA-4 immunotherapy improved survival in squamous NSCLC compared with chemotherapy, according to results of the phase III PRESERVE-003 trial. #WCLC26 @iaslc.bsky.social
https://www.medpagetoday.com/meetingcoverage/iaslc/123012